RESEARCH ARTICLE
Hydroxyl Ethyl Cellulose HHX and Polymethyl Methacrylate Based Site Specific Floating Delivery of Prochlorperazine Maleate
Swati C. Jagdale*, Aleesha B. Randhave
Article Information
Identifiers and Pagination:
Year: 2016Volume: 3
First Page: 149
Last Page: 163
Publisher Id: PHARMSCI-3-149
DOI: 10.2174/1874844901603010149
Article History:
Received Date: 16/03/2016Revision Received Date: 25/05/2016
Acceptance Date: 27/05/2016
Electronic publication date: 28/07/2016
Collection year: 2016
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Background:
Prochlorperazine maleate is a phenothiazine antipsychotic used principally in the treatment of nausea, vomiting and vertigo. Biological half- life of the drug is about 6 to 8 hrs and oral dose is 5 or 10 mg thrice or four times a day. The mean absolute bioavailability for drug is 12.5%. Due to the solubility of drug in acidic pH, it is mainly absorbed from stomach.
Objective:
Site specific oral floating delivery of prochlorperazine maleate will prolong the gastric retention time, increases the drug bioavailability, reduces frequency of administration and can result in better patient compliance.
Method:
The tablets were prepared by direct compression technique. Floating drug delivery was developed using gas forming agent and release retarding agent i.e. hydroxyethyl cellulose HHX (Natrosol HHX) and polymethyl methacrylate (PMMA). 32 full factorial design was used for optimization. Prepared tablets were evaluated for pre and post compression parameters.
Results:
From the factorial batches it was observed that formulation containing 68.5% of hydroxyethyl cellulose HHX and 15% of polymethyl methacrylate had shown a drug release of 91.56 ± 2.7% with floating upto 10 hrs following Korsmeyer Peppas release kinetics.
Conclusion:
In- vivo placebo X-ray study for optimized batch F6 had shown good gastroretention ability for 6 ± 0.5 hrs. In- vitro and in- vivo study confirmed the site specific floating delivery for drug.
